Skip to main content
Premium Trial:

Request an Annual Quote

Teaching Congress a Thing (or Ten)

This blog post follows up on an article in the Washington Post about the long road that lies ahead for companies hoping to gain approval for biogenerics. The article follows Insmed's CEO, Geoffrey Allan, who has been advising Congress on drug pharmacology in order to speed up the approval process. "However, the applicant must provide evidence that its product will produce the same clinical result as the brand product in any given patient and that it presents no additional safety risks or diminished efficacy if a patient alternates or is switched between products. This will be a tough road to travel," says a post at Patent Baristas.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.